Investigators found data from the National Notifiable Diseases Surveillance System that showed hepatitis C virus infection rates doubled among women of reproductive age between 2006 and 2014.
Further patient advocacy is needed to ensure that recipients of HCV-infected organs have access to direct-acting antivirals as early as possible, including in a prophylactic manner, if data continue to support its benefit.
Although hepatic vein pressure gradient measurement is an accurate method for evaluation of portal HTN, this technique is invasive and not widely available.
The opioid epidemic has fueled the transmission of HCV, particularly among younger persons, who are often unaware of their risks and prevented from receiving timely treatment due to a variety of care barriers, even in settings ideally suited to identifying and treating HCV.
Investigators conducted a secondary analysis that assessed virologic outcomes following 48 weeks of first-line treatment with dolutegravir/lamivudine in patients with newly diagnosed HIV infection.
Researchers conducted a modeling study to determine the projected long-term impact of the COVID-19 pandemic on outcomes associated with hepatitis C virus care.
Forty years after the emergence of HDV, the first anti-HDV therapeutic has been approved by the EMA, indicating the dawn of a new era for this difficult to treat disease
Investigators conducted a study that compared the efficacy of high- vs standard-dose hepatitis B virus revaccination regimens in patients with HIV infection.
In this phase 4 non-inferiority trial, researchers compared the effects of short course vs standard course therapy with sofosbuvir-velpatasvir for the treatment of patients with hepatitis C virus.
Researchers conducted a cross-sectional study to assess the impact of subscription-based payment models on the rate of prescription fills for hepatitis C virus medications among individuals in Louisiana and Washington enrolled in Medicaid.
Investigators reported on the hepatitis C virus cascade of care throughout the first few years of a treatment-as-prevention program initiated in Iceland.
Investigators conducted an ongoing prospective cohort study to better understand the safety and efficacy of nucleoside and/or nucleotide analogs among patients with hepatitis B virus-related acute-on-chronic liver failure.
Researchers used real-world data to determine the impact of hepatic fibrosis on the effectiveness of sofosbuvir/velpatasvir treatment in an Asian population with hepatitis C virus infection.
Researchers studied the impact of current opioid agonist therapy on initiation of chronic hepatitis C virus treatment among a population of individuals who inject drugs.
Researchers attempted to determine if medications for opioid use disorder integrated with infectious disease measures can lead to better infectious disease outcomes.
Findings emphasize the importance of strategies to help HBV-HIV coinfected patients maximize antiretroviral adherence to achieve hepatitis B viral suppression.
Investigators estimated the incidence of HBsAg seroclearance in patients with hepatitis B virus infection on long-term therapy with entecavir or tenofovir disoproxil fumarate.
